Example: bankruptcy
ANEXO I FICHA TÉCNICA O RESUMEN DE LAS …
2 1. NOMBRE DEL MEDICAMENTO STELARA 130mg concentrado para solución para perfusión 2. COMPOSICIÓN CUALITATIVA Y CUANTITATIVA Cada vial contiene 130mg de ustekinumab en 26ml (5mg/ml).
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
MEDICATION GUIDE STELARA (stel ar’ a) …
www.janssenlabels.com2 STELARA® (ustekinumab) Before you receive STELARA, tell your doctor about all of your medical conditions, including if you: • have any of the conditions or symptoms listed in the section “What is the most important information I should know about STELARA?” • ever had an allergic reaction to STELARA.
Notice : information de l’utilisateur STELARA 45 mg ...
www.janssen.comNotice : information de l’utilisateur . STELARA 45 mg solution injectable . Ustekinumab . Veuillez lire attentivement cette notice avant d’utiliser ce médicament car elle contient des
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eu2 1. NAME OF THE MEDICINAL PRODUCT STELARA 130mg concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 130mg ustekinumab in 26mL(5mg/mL).
Stelara® (ustekinumab) Specialty Medication ...
www.aetna.comStelara® (ustekinumab) Specialty Medication Precertification Request Page 3 of 3 (Please return Pages 1 to 3 for precertification of medications.) Aetna …
Procedures, programs and drugs you must precertify
www.aetna.comProcedures, programs and drugs you must precertify Participating provider precertification list Effective July 1, 2018 . Applies to. 1,2,3,4,9: Aetna